Stock Track | KEYMED BIO-B Stock Soars on China Approval for Atopic Dermatitis Drug

Stock Track09-13

Shares of KEYMED Biosciences Inc. (02162.HK) surged by 6.89% on Thursday after the Hong Kong-based biopharmaceutical company received a significant regulatory approval for one of its lead drug candidates.

The company announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval paves the way for KEYMED to commercialize and sell Stapokibart in the vast Chinese pharmaceutical market, a critical milestone for the company's pipeline.

Investors welcomed the news, driving KEYMED's stock price up by nearly 7% in intraday trading. Analysts praised the approval as a crucial step forward for the company, with some raising their price targets and rating recommendations for the stock. The positive market reaction underscores the significance of the NMPA approval and the potential for Stapokibart to generate substantial revenue for KEYMED in the Chinese market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123653323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-13 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123653323","market":"us","top_or_hot":-1,"title":"Stock Track | KEYMED BIO-B Stock Soars on China Approval for Atopic Dermatitis Drug","media":"Stock Track","content":"<p>Shares of KEYMED Biosciences Inc. (02162.HK) surged by 6.89% on Thursday after the Hong Kong-based biopharmaceutical company received a significant regulatory approval for one of its lead drug candidates.</p>\n\n<p>The company announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval paves the way for KEYMED to commercialize and sell Stapokibart in the vast Chinese pharmaceutical market, a critical milestone for the company's pipeline.</p>\n\n<p>Investors welcomed the news, driving KEYMED's stock price up by nearly 7% in intraday trading. Analysts praised the approval as a crucial step forward for the company, with some raising their price targets and rating recommendations for the stock. The positive market reaction underscores the significance of the NMPA approval and the potential for Stapokibart to generate substantial revenue for KEYMED in the Chinese market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | KEYMED BIO-B Stock Soars on China Approval for Atopic Dermatitis Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | KEYMED BIO-B Stock Soars on China Approval for Atopic Dermatitis Drug\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-13 22:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of KEYMED Biosciences Inc. (02162.HK) surged by 6.89% on Thursday after the Hong Kong-based biopharmaceutical company received a significant regulatory approval for one of its lead drug ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1123653323","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123653323","pubTimestamp":1726236281,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of KEYMED Biosciences Inc.  surged by 6.89% on Thursday after the Hong Kong-based biopharmaceutical company received a significant regulatory approval for one of its lead drug candidates.The company announced that China's National Medical Products Administration  has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval paves the way for KEYMED to commercialize and sell Stapokibart in the vast Chinese pha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"股票赛道康康生物-B股价因中国批准特应性皮炎药物而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Shares of KEYMED Biosciences Inc. (02162.HK) surged by 6.89% on Thursday after the Hong Kong-based biopharmaceutical company received a significant regulatory approval for one of its lead drug candidates.\nThe company announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval paves the way for KEYMED to commercialize and sell Stapokibart in the vast Chinese pharmaceutical market, a critical milestone for the company's pipeline.\nInvestors welcomed the news, driving KEYMED's stock price up by nearly 7% in intraday trading. Analysts praised the approval as a crucial step forward for the company, with some raising their price targets and rating recommendations for the stock. The positive market reaction underscores the significance of the NMPA approval and the potential for Stapokibart to generate substantial revenue for KEYMED in the Chinese market.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123653323"}